Biogen didn't have much success on the market with multiple sclerosis med Zinbryta, and now the drug is at the center of a discrimination and retaliation lawsuit by a former manager.
The Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that Zinbryta (daclizumab) “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.”